FDA warns of MI, death risk with regadenoson, adenosine

被引：0

|

作者：

机构：

来源：

Reactions Weekly | 2013年 / 1481卷 / 1期

关键词：

D O I：

10.1007/s40278-013-7556-y

中图分类号：

学科分类号：

摘要：

引用

收藏

页码：3 / 3

相关论文

共 50 条

[1] FDA Issues Warning on Regadenoson and Adenosine
不详
[J]. JOURNAL OF NUCLEAR MEDICINE, 2014, 55 (01):
[2] FDA warns of kidney disorders, MI and stroke with Trasylol
[J]. Reactions Weekly, 2006, 1089 (1) : 3 - 3
[3] FDA warns of seizure risk with dalfampridine
[J]. Reactions Weekly, 2012, 1412 (1) : 2 - 2
[4] US FDA warns of heart issues, death with clarithromycin
[J]. Reactions Weekly, 2018, 1692 (1) : 7 - 7
[5] Antidepressants: FDA warns of paediatric suicide risk
[J]. Reactions Weekly, 2003, 976 (1) : 2 - 2
[6] FDA WARNS OF RISK FROM HORMONE PRODUCTS
不详
[J]. JAVMA-JOURNAL OF THE AMERICAN VETERINARY MEDICAL ASSOCIATION, 2018, 253 (08): : 949 - 949
[7] FDA warns of risk of peripheral neuropathy with fluoroquinolones
[J]. Reactions Weekly, 2013, 1466 (1) : 2 - 2
[8] FDA warns of risk of intrathecal injection of tranexamic acid
[J]. Reactions Weekly, 2020, 1835 (1) : 1 - 1
[9] Risk of differentiation syndrome with enasidenib, warns US FDA
[J]. Reactions Weekly, 2018, 1732 (1) : 4 - 4
[10] Vinpocetine during pregnancy: FDA warns of safety risk
[J]. Reactions Weekly, 2019, 1757 (1) : 8 - 8

← 1 2 3 4 5 →